Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
The latest update is out from Lumos Pharma ( (LUMO) ).
Lumos Pharma, Inc. has announced the completion of its merger with DPV Parent, Inc. which resulted in the delisting of its shares from Nasdaq. The merger agreement involved a tender offer by DPV MergerSub, Inc., a wholly owned subsidiary of DPV Parent, to purchase all outstanding shares of Lumos Pharma’s common stock for a cash amount plus contingent value rights. Consequently, all equity incentive plans and controlled equity agreements were terminated, and former Lumos shareholders and option holders will receive cash and contingent value rights as per the agreement terms. These changes signal a significant restructuring and a shift in market positioning for Lumos Pharma, impacting its stakeholders by transforming the company’s operational structure and shareholding framework.
More about Lumos Pharma
YTD Price Performance: 36.48%
Average Trading Volume: 93,039
Technical Sentiment Consensus Rating: Hold
Current Market Cap: $37.54M
For an in-depth examination of LUMO stock, go to TipRanks’ Stock Analysis page.
Trending Articles
- Class Action Lawsuit Against Terran Orbital Corporation (LLAP)
- Shareholder Alert Against ASML Holding N.V. (NASDAQ:ASML)
- Google-Samsung Launch Android XR OS to Compete with Apple and Meta
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
